GlassScriptPhysician profile
David James Draper
NPI 1083641856
$3,089.50
in general payments reported to CMS, 2019-2025
24 companies · $523 in 2025
The $523 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.11 · 2020: $172 · 2021: $24.04 · 2022: $1,723 · 2023: $269 · 2024: $364 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133 · Education: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.08 |
| Education | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,793.78 | 2022-2025 | Calquence |
| Novartis Pharmaceuticals Corporation | $324.25 | 2022-2025 | |
| Abbvie INC. | $299.33 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2020 | |
| Pfizer INC. | $119.41 | 2019-2025 | |
| Seagen INC. | $61.58 | 2023 | Padcev |
| Celgene Corporation | $46.47 | 2021-2025 | Reblozyl |
| Aveo Pharmaceuticals, INC. | $38.72 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $30.00 | 2023 | Imbruvica |
| Kyowa Kirin, INC. | $21.87 | 2020 | |
| Tersera Therapeutics LLC | $20.96 | 2024 | Zoladex |
| Springworks Therapeutics, INC. | $20.25 | 2024 | Ogsiveo |
| Eisai INC. | $19.29 | 2023 | |
| Incyte Corporation | $17.51 | 2025 | Jakafi |
| Myovant Sciences INC. | $17.39 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $16.68 | 2023 | |
| Puma Biotechnology, INC. | $16.47 | 2023 | |
| Merck Sharp & Dohme LLC | $16.20 | 2024 | Keytruda |
| Cti Biopharma Corp. | $16.01 | 2023 | Vonjo |
| Amgen INC. | $15.83 | 2022 | |
| Daiichi Sankyo INC. | $14.87 | 2024 | Injectafer |
| Astellas Pharma US INC | $12.63 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Draper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.